Nexentis Technologies' Subsidiary MitoCareX Bio Completes Initial Computational Screening with Boltz
Nexentis Technologies Inc. announced that its subsidiary, MitoCareX Bio Ltd., has finished the first computational screening phase of its drug-discovery collaboration with AI research lab Boltz, PBC.